Novan Inc. (NASDAQ:NOVN) has released a priority update about its lead product SB206, which they are currently evaluating in a pivotal third phase B-SIMPLE study in Molluscum. The results of the latter are expected in Q2 2021.
Novan dosing patients in Phase 3 B-SIMPLE study
Besides the focus on SB206 for Molluscum, Novan is also directing the Pre-IND development process towards the continuing in vitro activities associated with coronaviridae and exploring the potential of NITRICIL™ platform tech in antimicrobial indication for pets.
Paula Brown Stafford, the CEO and President of the company stated that in the last few months, Novan has dedicated its efforts and time to evaluate an internal pipeline in late stages, underlying NITRICIL technology, and the broader dermatology platform. She added that the components represent a solid foundation for the company to build its moment and support the next growth phase. Stanford said that currently, the focus is the successful execution of the third phase pivotal SB206 study for molluscum treatment, which currently is ongoing with the dosing of patients. She lauded the progress the Novan team has made ion evaluation of the program.
Novan advancing NITRICIL in indications in animal health
Besides the SB206 program, Stafford said that Novan has continued to make progress in the in vitro work evaluating NITRICIL™’s ability to target replication mechanisms of SARS-COV-2. The company is optimistic about reporting the results from the assessment before the end of the year. She said that so far, the company has launched exploratory efforts evaluating NITRICL use for antimicrobial indications in animal health. This is an area that Novan is upbeat that will diversify its pipeline and also offer opportunities in a related and important market. So far, the company has sought animal health experts’ services to help assess the technical feasibility and market potential.
Stafford concludes that in addition to the progress made in advancing their priority programs, they have a wide pipeline of possible expansion opportunities in dermatology, women’s and men’s health, and gastroenterology conditions. Novan is reviewing its current programs and opportunities, which will expand its priority development efforts.
